Outcomes and Prognostic Factors of Magnetic Resonance-guided Focused Ultrasound Thalamotomy for Essential Tremor at 2-year Follow-up

• DOI: 10.2176/jns-nmc.2023-0202
• Publication Date: 2024-02-14T22:14:24Z
• Authors: Miki HASHIDA; Satoshi MAESAWA; Sachiko KATO; Daisuke NAKATSUBO; Takahiko TSUGAWA; Jun TORII; Takafumi TANEI; Tomotaka ISHIZAKI; Manabu MUTOH; Yoshiki ITO; Takashi TSUBOI; Satomi MIZUNO; Masashi SUZUKI; Toshihiko WAKABAY...; Masahisa KATSUNO; Ryuta SAITO
• Keywords: Magnetic Resonance Spectroscopy; Essential Tremor; Neurosciences. Biological psychiatry. Neuropsychiatry; Prognosis; ablation; Magnetic Resonance Imaging; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Thalamus; Tremor; outcome; focused ultrasound; Humans; Special Topic; essential tremor; prognostic factor; RC321-571; Follow-Up Studies; Retrospective Studies

Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for essential tremor (ET). However, its long-term outcomes and prognostic factors remain unclear. This study aimed to retrospectively investigate 38 patients with ET who underwent MRgFUS thalamotomy and were followed up for >2 years. The improvement in tremor was evaluated using the Clinical Rating Scale for Tremor (CRST). Adverse events were documented, and correlations with factors, such as skull density ratio (SDR), maximum mean temperature (T-max), and lesion size, were examined. Furthermore, the outcomes were compared between two groups, one that met the cutoff values, which was previously reported (preoperative CRST-B ≤ 25, T-max ≥ 52.5°C, anterior-posterior size of lesion ≥ 3.9 mm, superior-inferior [SI] size of lesion > 5.5 mm), and the other that did not. The improvement rate was 59.4% on average at the 2-year follow-up. Adverse events, such as numbness (15.8%), dysarthria (10.5%), and lower extremity weakness (2.6%), were observed even after 2 years, although these were mild. The factors correlated with tremor improvement were the T-max and SI size of the lesion (p < 0.05), whereas the SDR showed no significance. Patients who met the aforementioned cutoff values demonstrated a 69.8% improvement at the 2-year follow-up, whereas others showed a 43.6% improvement (p < 0.05). In conclusion, MRgFUS is effective even after 2 years. The higher the T-max and the larger the lesion size, the better the tremor control. Previously reported cutoff values clearly predict the 2-year prognosis, indicating the usefulness of MRgFUS.